Chemours (NYSE:CC) Given "Neutral" Rating at Mizuho

Key Points

• Mizuho reiterated its “Neutral” rating on Chemours and lowered its price target to $15 from $18, implying approximately 14% upside from the prior close.
• Analyst sentiment remains cautious: Chemours has an average “Hold” rating and a consensus price target of $18.09, while the stock recently traded near $13.16 after declining 1.7%.
• The company missed quarterly earnings and revenue expectations, reporting $0.42 EPS versus $0.49 expected and $1.59 billion in revenue versus $1.65 billion forecast. Insiders have nevertheless purchased 8,663 shares worth about $130,601 over the past 90 days.

Chemours (NYSE:CC - Get Free Report)'s stock had its "neutral" rating reiterated by Mizuho in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $15.00 price target on the specialty chemicals company's stock, down from their prior price target of $18.00. Mizuho's price objective would suggest a potential upside of 13.95% from the company's previous close.

Several other research firms have also recently weighed in on CC. Truist Financial cut their target price on shares of Chemours from $30.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Zacks Research upgraded shares of Chemours from a "strong sell" rating to a "hold" rating in a research note on Thursday, September 10th. Weiss Ratings downgraded shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, August 6th. The Goldman Sachs Group restated a "neutral" rating and set a $16.00 price objective on shares of Chemours in a research report on Friday. Finally, UBS Group cut their price objective on Chemours from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Monday, October 5th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Chemours has an average rating of "Hold" and a consensus target price of $18.09.

Chemours Trading Down 1.7%

CC stock opened at $13.16 on Wednesday. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -6.89 and a beta of 1.41. The business has a 50 day simple moving average of $14.83 and a two-hundred day simple moving average of $19.03.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.65 billion. During the same period last year, the business earned ($2.54) earnings per share. The company's quarterly revenue was down 1.5% compared to the same quarter last year. Research analysts anticipate that Chemours will post 0.87 EPS for the current fiscal year.

Insider Buying and Selling

In other Chemours news, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares of the company's stock, valued at $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shane Hostetter acquired 3,350 shares of the stock in a transaction on Thursday, August 6th. The shares were acquired at an average price of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer directly owned 102,698 shares of the company's stock, valued at $1,534,308.12. The trade was a 3.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 8,663 shares of company stock worth $130,601. Insiders own 0.85% of the company's stock.

Institutional Trading of Chemours

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Chemours in the second quarter worth approximately $477,769,000. Wolf Hill Capital Management LP purchased a new position in Chemours during the 2nd quarter valued at $59,698,056. Bank of New York Mellon Corp purchased a new position in Chemours during the 2nd quarter valued at $33,353,000. Legal & General Group Plc bought a new position in Chemours in the 2nd quarter valued at $28,400,000. Finally, Bank of America Corp DE grew its position in Chemours by 79.1% in the 1st quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company's stock valued at $29,014,000 after acquiring an additional 581,621 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Chemours, providing some support for the stock and signaling that the firm sees longer-term value despite near-term operating challenges. BMO Capital Reaffirms Buy Rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, suggesting a balanced risk-reward view rather than a clear bullish or bearish recommendation. Barclays Initiates Coverage
• Negative Sentiment: RBC downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22. RBC cited persistent weakness in titanium dioxide, or TiO2, and anticipated headwinds in the Thermal & Specialized Solutions segment through year-end. The downgrade reinforces concerns about weak demand and limited near-term earnings momentum. RBC Downgrades Chemours
• Negative Sentiment: A securities class action has been filed against Chemours and certain officers. The lawsuit alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand before an approximately 18% stock decline. Additional law firms are soliciting investors ahead of the December 7, 2026 lead-plaintiff deadline. The allegations have not been proven, but the litigation adds legal, reputational and potential financial overhang. Pomerantz Class Action Filing

About Chemours

The Chemours Company NYSE: CC is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.